GO:0017188 L-aspartate N-acetyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0017188 defines the enzymatic activity that transfers an acetyl group from acetyl-CoA to L-aspartate, producing N-acetyl-L-aspartate (NAA) and CoA.
• The human enzyme responsible is aspartate N-acetyltransferase (ANAT), encoded by NAT8L, and its loss-of-function mutations cause hypoacetylaspartia, a severe neurological disorder.
• ANAT is highly enriched in the nervous system, where it drives the synthesis of NAA, one of the most abundant metabolites in the mammalian brain.
• NAA produced by this activity serves as a major source of acetyl groups for lipid synthesis during early brain development.
• ANAT is a validated therapeutic target for Canavan disease, and multiple inhibitor scaffolds have been developed and optimized.
• Studying GO:0017188 requires integrating enzymology, metabolic tracing, and CRISPR-based models to dissect its role in health and disease.
Description
L-aspartate N-acetyltransferase activity (GO:0017188) is a molecular function that catalyzes the acetylation of L-aspartate using acetyl-CoA as the acetyl donor, yielding N-acetyl-L-aspartate (NAA), coenzyme A, and a proton. This reaction is the committed step in the biosynthesis of NAA, a metabolite that is abundant in the vertebrate nervous system and serves both as an osmolyte and as a reservoir of acetyl groups. The enzyme responsible for this activity in humans is aspartate N-acetyltransferase (ANAT), encoded by the NAT8L gene, and its identification provided a molecular explanation for the metabolic disorder hypoacetylaspartia. Because NAA levels are tightly linked to brain development and function, the activity defined by GO:0017188 has become a focal point for researchers studying neurodevelopment, myelin lipid synthesis, and neurodegenerative conditions. The reaction catalyzed by ANAT is unusual in that it uses acetyl-CoA directly, rather than acetyl phosphate or another donor, to acetylate an amino acid. This makes the enzyme a key node at the intersection of amino acid metabolism and acetyl-CoA homeostasis, particularly in the brain where acetyl-CoA is also required for lipid synthesis and neurotransmitter production. Quantitative studies using 13C magnetic resonance spectroscopy have shown that NAA synthesis in the human brain is rapid, underscoring the physiological importance of this activity. Consequently, GO:0017188 is not merely a biochemical annotation; it represents a critical control point in brain metabolism with direct implications for disease. For researchers, GO:0017188 provides a precise functional handle to investigate how aspartate acetylation contributes to normal physiology and to pathologies such as Canavan disease, hypoacetylaspartia, and potentially other neurological conditions. The availability of high-throughput screening assays and bisubstrate analog inhibitors has further enabled pharmacological interrogation of this activity. This article synthesizes the current understanding of GO:0017188, its gene products, regulatory context, disease relevance, and the experimental methods used to study it.
L-aspartate N-acetyltransferase activity At A Glance
| GO ID | GO:0017188 |
|---|---|
| GO term | L-aspartate N-acetyltransferase activity |
| Ontology | molecular_function |
| Synonym | acetyl-CoA:L-aspartate N-acetyltransferase activity; aspartate N-acetyltransferase activity |
| Definition | Catalysis of the reaction: L-aspartate + acetyl-CoA = N-acetyl-L-aspartate + CoA + H+. |
| Major function | Biosynthesis of N-acetyl-L-aspartate (NAA) by acetyl transfer from acetyl-CoA to L-aspartate. |
| Human gene | NAT8L encodes aspartate N-acetyltransferase (ANAT). |
| Tissue distribution | Predominantly expressed in the nervous system, with high activity in brain regions. |
| Disease relevance | Mutations cause hypoacetylaspartia; enzyme is a target for Canavan disease therapy. |
What Is GO:0017188?
GO:0017188, L-aspartate N-acetyltransferase activity, is defined as the catalysis of the reaction: L-aspartate + acetyl-CoA = N-acetyl-L-aspartate + CoA + H+. In other words, it is the enzyme activity that attaches an acetyl group from acetyl-CoA onto the amino group of L-aspartate, forming NAA and releasing coenzyme A and a proton. This activity is synonymous with acetyl-CoA:L-aspartate N-acetyltransferase activity and aspartate N-acetyltransferase activity.
Why Is L-aspartate N-acetyltransferase activity Important in Cell Biology?
GO:0017188 is important because it defines the only known enzymatic route for the synthesis of N-acetyl-L-aspartate (NAA), a metabolite that is among the most abundant in the mammalian brain and is essential for normal neurological function. The activity is directly linked to human disease: loss-of-function mutations in the gene encoding this activity cause hypoacetylaspartia, a severe neurodevelopmental disorder, and dysregulation of NAA metabolism is a hallmark of Canavan disease. Moreover, the acetyl-CoA consumed by this reaction places it at the center of brain energy and lipid metabolism, influencing myelin synthesis during development. Therefore, understanding GO:0017188 is critical for both basic neurochemistry and therapeutic development.
• Provides the sole enzymatic source of N-acetyl-L-aspartate (NAA) in the brain.
• Mutations in NAT8L, the gene encoding this activity, cause hypoacetylaspartia, a severe neurological disorder.
• The activity is a validated drug target for Canavan disease, a fatal leukodystrophy.
• NAA produced by this activity serves as a major acetyl donor for lipid synthesis during brain development.
• ANAT activity is enriched in the nervous system, with differential distribution across brain regions.
• Quantitative 13C MRS studies show rapid NAA synthesis in the human brain, highlighting the activity's physiological importance.
• The enzyme competes with other acetyl-CoA-consuming pathways, linking amino acid metabolism to energy homeostasis.
• High-throughput screening cascades have been developed to identify inhibitors of this activity.
• Bisubstrate analog inhibitors provide chemical tools to probe the enzyme's mechanism and therapeutic potential.
• Understanding this activity aids interpretation of NAA peaks in magnetic resonance spectroscopy, a common clinical readout.
Molecular Mechanism of L-aspartate N-acetyltransferase activity
Substrate recognition and binding
In simple terms: The enzyme grabs L-aspartate and acetyl-CoA, holding them in the right orientation for a chemical reaction.
ANAT, the enzyme responsible for GO:0017188, binds L-aspartate and acetyl-CoA in a sequential manner. The enzyme exhibits specificity for L-aspartate as the acetyl acceptor, and acetyl-CoA as the acetyl donor. Structural and kinetic studies of ANAT and its homologs indicate that the active site accommodates the amino group of aspartate and the thioester bond of acetyl-CoA in close proximity, facilitating direct acetyl transfer. The reaction produces NAA, CoA, and a proton, and is essentially irreversible under physiological conditions.
Catalytic mechanism and cofactors
In simple terms: The enzyme transfers an acetyl group from one molecule to another without needing extra cofactors beyond acetyl-CoA itself.
The catalytic mechanism of ANAT involves nucleophilic attack of the aspartate amino group on the acetyl carbonyl of acetyl-CoA, forming a tetrahedral intermediate and releasing CoA. Unlike some acetyltransferases, ANAT does not require metal ions or other cofactors; acetyl-CoA serves both as the acetyl donor and as an essential binding partner. The reaction is classified as an N-acetyltransferase (EC 2.3.1.-) and is driven by the hydrolysis of the acetyl-CoA thioester bond. Bisubstrate analog inhibitors that mimic the transition state have been designed to block this mechanism, confirming the ordered binding of substrates.
Regulation by substrate availability and cellular context
In simple terms: How much NAA is made depends on how much aspartate and acetyl-CoA are available inside the cell.
The activity of ANAT is influenced by the intracellular concentrations of its substrates, L-aspartate and acetyl-CoA. In septal SN56 cholinergic cells, exposure to excess zinc alters the interplay between NAA and acetyl-CoA levels, suggesting that ANAT activity is sensitive to metabolic perturbations. Because acetyl-CoA is a central metabolite, conditions that affect its availability, such as changes in glucose metabolism or lipid synthesis, can indirectly modulate NAA production. Additionally, the expression level of NAT8L is a key determinant of ANAT activity, as the enzyme is not known to be regulated by post-translational modifications in vivo.
Tissue-specific distribution and physiological role
In simple terms: This enzyme is mostly found in the brain, where it makes a molecule that helps nerve cells work properly.
The activity defined by GO:0017188 is differentially distributed in the nervous system, with high levels in specific brain regions. This distribution correlates with the regional synthesis of NAA, which is used as an osmolyte and as a precursor for the neurotransmitter N-acetylaspartylglutamate (NAAG). During early brain development, NAA derived from ANAT activity is a major source of acetyl groups for lipid synthesis, supporting myelin formation. In the adult human brain, 13C MRS studies have quantified the NAA synthesis rate, demonstrating that the activity remains robust throughout life.
Inhibition and pharmacological targeting
In simple terms: Scientists have made molecules that can block this enzyme, which could help treat certain brain diseases.
Because ANAT activity is a therapeutic target for Canavan disease, several inhibitor classes have been developed. High-throughput screening cascades have identified small-molecule inhibitors of human ANAT. Structure-guided optimization led to potent aspartate N-acetyltransferase inhibitors with drug-like properties. Bisubstrate analogs that mimic the ternary complex of aspartate and acetyl-CoA have also been synthesized and evaluated as critical brain enzyme inhibitors. These chemical tools are valuable for validating the role of GO:0017188 in disease models and for exploring the consequences of enzyme inhibition.
Key Genes Involved in GO:0017188 L-aspartate N-acetyltransferase activity
The following genes and proteins are directly or indirectly associated with L-aspartate N-acetyltransferase activity (GO:0017188) and its metabolic context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NAT8L | Encodes aspartate N-acetyltransferase (ANAT), the enzyme catalyzing GO:0017188 | Primary target for knockout, mutation, and overexpression studies; mutations cause hypoacetylaspartia |
| ASPA | Encodes aspartoacylase, which hydrolyzes NAA to aspartate and acetate | Defects cause Canavan disease; used to study NAA turnover and ANAT flux |
| SLC25A12 | Mitochondrial aspartate-glutamate carrier, supplies aspartate for NAA synthesis | Modulates substrate availability for ANAT; relevant to metabolic studies |
| ACLY | ATP-citrate lyase, produces acetyl-CoA from citrate | Influences acetyl-CoA pools that feed ANAT activity |
| ACSS2 | Acetyl-CoA synthetase 2, generates acetyl-CoA from acetate | Alternative acetyl-CoA source; may affect NAA synthesis in brain |
| PDHA1 | Pyruvate dehydrogenase, produces acetyl-CoA from pyruvate | Links glucose metabolism to acetyl-CoA supply for ANAT |
| SLC25A1 | Mitochondrial citrate carrier, exports citrate for acetyl-CoA production | Indirectly supports ANAT activity by providing acetyl-CoA |
| NAT8 | Kidney-specific N-acetyltransferase, homolog of NAT8L | Used in comparative studies of N-acetyltransferase evolution and specificity |
| GCPII | Glutamate carboxypeptidase II, involved in NAAG metabolism | NAAG is derived from NAA; links ANAT activity to neurotransmission |
| NAAG synthetase | Enzyme that converts NAA to NAAG | Downstream of ANAT; relevant to neuronal signaling studies |
| SLC25A18 | Mitochondrial glutamate carrier, supports aspartate metabolism | May influence substrate supply for ANAT |
| GOT1 | Cytosolic aspartate aminotransferase, interconverts aspartate and oxaloacetate | Regulates aspartate availability for ANAT |
| GOT2 | Mitochondrial aspartate aminotransferase, produces aspartate | Contributes to aspartate pool used by ANAT |
| PC | Pyruvate carboxylase, anaplerotic enzyme producing oxaloacetate | Supports aspartate synthesis and thus ANAT activity |
| MDH1 | Malate dehydrogenase, part of malate-aspartate shuttle | Indirectly affects aspartate and acetyl-CoA balance |
| SLC1A3 | Glutamate transporter, influences aspartate levels | Modulates extracellular aspartate available for uptake |
| SLC1A2 | Glutamate transporter, regulates neurotransmitter pools | May affect aspartate homeostasis and ANAT substrate supply |
| NAT8B | Putative N-acetyltransferase, related to NAT8L | Used in phylogenetic and functional comparisons |
How Is L-aspartate N-acetyltransferase activity Regulated?
The activity of L-aspartate N-acetyltransferase (GO:0017188) is primarily regulated by the expression level of its gene, NAT8L, and by the availability of its substrates, L-aspartate and acetyl-CoA. There is no strong evidence for allosteric regulation or post-translational modification of ANAT in vivo. However, metabolic conditions that alter acetyl-CoA pools, such as changes in glucose oxidation or lipid synthesis, can indirectly modulate flux through this activity. In septal SN56 cholinergic cells, excess zinc disrupts the balance between NAA and acetyl-CoA, suggesting that trace metal homeostasis can influence ANAT activity. Additionally, developmental stage affects ANAT expression, with high activity during periods of active myelination. The enzyme's product, NAA, can be further metabolized by aspartoacylase (ASPA), and the interplay between synthesis and degradation determines steady-state NAA levels.
L-aspartate N-acetyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NAT8L | Hypoacetylaspartia (loss-of-function) | Knockout or point-mutation knock-in in neuronal cell lines; patient-derived iPSCs |
| ASPA | Canavan disease (NAA accumulation) | ASPA knockout mice; overexpression of ANAT to model NAA excess |
| NAT8L | Canavan disease (therapeutic target) | Enzyme inhibition assays; CRISPR knockout to validate target engagement |
| NAT8L | Brain development and myelination | Conditional knockout in oligodendrocytes; lipid synthesis tracing |
| NAT8L | Zinc-induced metabolic stress | SN56 cholinergic cells with zinc exposure; CRISPR knockout of NAT8L |
Hypoacetylaspartia and NAT8L mutations
Loss-of-function mutations in NAT8L, the gene encoding aspartate N-acetyltransferase, cause hypoacetylaspartia, a rare neurometabolic disorder characterized by severely reduced NAA levels in the brain. Patients present with developmental delay, hypotonia, and seizures, highlighting the essential role of GO:0017188 in normal neurological function. This condition is distinct from Canavan disease, which is caused by mutations in ASPA, the enzyme that degrades NAA. However, both disorders underscore the importance of NAA homeostasis in the brain.
Canavan disease and therapeutic targeting of ANAT
Canavan disease is a fatal leukodystrophy caused by deficiency of aspartoacylase (ASPA), leading to accumulation of NAA. Because ANAT catalyzes the synthesis of NAA, inhibiting this activity is a rational therapeutic strategy to reduce NAA levels in Canavan disease. High-throughput screening has identified small-molecule inhibitors of human ANAT, and structure-guided optimization has produced potent compounds with improved drug-like properties. Bisubstrate analog inhibitors have also been developed as critical brain enzyme inhibitors, providing proof-of-concept for pharmacological intervention. These efforts demonstrate the direct link between GO:0017188 and a devastating human disease.
NAA metabolism in brain development and lipid synthesis
During early brain development, NAA synthesized by ANAT is a major source of acetyl groups for lipid synthesis, which is required for myelin formation. Disruption of this activity could therefore impact myelination and white matter integrity. In animal models, reduced ANAT activity leads to decreased NAA and impaired lipid synthesis, suggesting a role for GO:0017188 in developmental myelination. This connection expands the disease relevance of the term beyond Canavan disease to broader white matter disorders.
Potential roles in neurodegeneration and metabolic stress
Alterations in NAA levels have been observed in various neurodegenerative conditions, and ANAT activity may be influenced by metabolic stress. In cholinergic cells exposed to excess zinc, a condition relevant to Alzheimer's disease, the interaction between NAA and acetyl-CoA is perturbed, suggesting that ANAT activity could be affected in neurodegeneration. However, direct evidence for ANAT dysregulation in common neurodegenerative diseases is still limited, and further research is needed to establish causality.
From L-aspartate N-acetyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of complete loss of ANAT activity on NAA levels? | NAT8L knockout cell lines or animal models |
| How do specific patient mutations affect enzyme function? | Point-mutation knock-in of NAT8L variants (e.g., hypoacetylaspartia mutations) |
| Can tagged ANAT be used to study localization and interactions? | Knock-in of FLAG- or GFP-tagged NAT8L at the endogenous locus |
| What happens when ANAT is overexpressed in non-neuronal cells? | Overexpression of NAT8L via lentiviral or CRISPR activation |
| Which genes modify the metabolic consequences of ANAT loss? | CRISPR library screening in NAT8L-knockout background |
| How does ANAT activity respond to changes in acetyl-CoA supply? | Knockout of ACLY or ACSS2 in combination with NAT8L overexpression |
How to Study the L-aspartate N-acetyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| HPLC or LC-MS/MS | NAA and CoA production | Enzyme kinetics and inhibitor screening |
| 13C MRS | NAA synthesis rate in vivo | Human brain metabolism studies |
| CRISPR knockout | Loss of ANAT activity | Functional studies in cell lines and animal models |
| Point-mutation knock-in | Effect of patient variants on enzyme function | Hypoacetylaspartia mutation analysis |
| Overexpression | Gain of ANAT activity | Modeling NAA excess and downstream effects |
| CRISPR library screening | Genes modifying ANAT-related phenotypes | Target discovery and pathway analysis |
| Immunohistochemistry | Regional distribution of ANAT protein | Brain tissue mapping |
| Metabolic tracing with 13C-glucose | Flux through NAA synthesis pathway | Developmental lipid synthesis studies |
Enzymatic assays for ANAT activity
Direct measurement of L-aspartate N-acetyltransferase activity is typically performed using purified enzyme or cell lysates, with L-aspartate and acetyl-CoA as substrates. The reaction can be monitored by detecting the formation of NAA or CoA using high-performance liquid chromatography (HPLC), mass spectrometry, or coupled enzymatic assays. High-throughput screening cascades have been developed to identify inhibitors, using fluorescence or absorbance-based readouts. These assays are essential for characterizing kinetic parameters and testing small molecules.
Metabolic tracing and NAA quantification
To study the activity in a cellular context, researchers use stable isotope tracing with 13C-labeled glucose or acetate, followed by magnetic resonance spectroscopy (MRS) or mass spectrometry to quantify NAA synthesis rates. In vivo 13C MRS has been used to measure NAA synthesis directly in the human brain, providing a non-invasive readout of ANAT activity. In cell culture, NAA levels can be measured by LC-MS/MS, and changes in response to genetic manipulation of NAT8L can be assessed.
Genetic manipulation and CRISPR screens
CRISPR-Cas9 knockout of NAT8L is a powerful approach to eliminate ANAT activity and study downstream effects on NAA metabolism, lipid synthesis, and cell viability. Point mutations identified in hypoacetylaspartia patients can be introduced via homology-directed repair to assess their impact on enzyme function. Overexpression of NAT8L using CRISPR activation or lentiviral vectors can model NAA excess. Additionally, CRISPR library screening can identify genes that modulate sensitivity to ANAT inhibition or that compensate for its loss.
Imaging and biomarker analysis
Magnetic resonance spectroscopy (MRS) allows non-invasive detection of NAA peaks in the brain, which serves as a biomarker for ANAT activity. In animal models, MRS can be used to monitor NAA levels longitudinally after genetic or pharmacological manipulation. Immunohistochemistry and fluorescence microscopy can localize ANAT in brain tissue, revealing its regional distribution. These methods complement biochemical assays and provide spatial and temporal information.
How CRISPR Can Be Used to Study GO:0017188 L-aspartate N-acetyltransferase activity
Knockout
CRISPR-Cas9 knockout of NAT8L completely abolishes L-aspartate N-acetyltransferase activity, providing a clean model to study the consequences of NAA depletion. Knockout cell lines can be used to measure changes in lipid synthesis, acetyl-CoA pools, and sensitivity to metabolic stress. In animal models, NAT8L knockout recapitulates key features of hypoacetylaspartia, including reduced NAA levels and neurological deficits. These models are essential for validating the role of GO:0017188 in brain development and disease.
Point Mutation
Point mutations in NAT8L identified in hypoacetylaspartia patients can be introduced into cell lines using CRISPR-Cas9 homology-directed repair. These knock-in models allow researchers to assess the impact of specific amino acid substitutions on enzyme stability, catalytic activity, and substrate binding. Such models are valuable for understanding genotype-phenotype correlations and for testing pharmacological chaperones or inhibitors.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) or fluorescent proteins (e.g., GFP) at the endogenous NAT8L locus enables real-time tracking of ANAT expression, localization, and interactions. Tagged knock-in models can be used for co-immunoprecipitation and proximity labeling to identify novel binding partners. Additionally, knock-in of inducible degron tags allows rapid depletion of ANAT to study acute effects on NAA metabolism.
Overexpression
Overexpression of NAT8L via CRISPR activation (CRISPRa) or lentiviral transduction increases ANAT activity and NAA production, modeling conditions of NAA excess. This is particularly useful for studying the consequences of NAA accumulation, as seen in Canavan disease, and for testing the efficacy of ANAT inhibitors. Overexpression models can also be used to identify downstream metabolic adaptations to increased NAA synthesis.
How EDITGENE Supports L-aspartate N-acetyltransferase activity Research
Researchers studying L-aspartate N-acetyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in NAA metabolism, neurological disease, or therapeutic response. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of GO:0017188 and its associated pathways.
Contact EDITGENE today to design your custom CRISPR model for L-aspartate N-acetyltransferase activity research.
Frequently Asked Questions About L-aspartate N-acetyltransferase activity
What is L-aspartate N-acetyltransferase activity?
L-aspartate N-acetyltransferase activity (GO:0017188) is the enzyme activity that catalyzes the transfer of an acetyl group from acetyl-CoA to L-aspartate, producing N-acetyl-L-aspartate (NAA), coenzyme A, and a proton.
What gene encodes L-aspartate N-acetyltransferase?
The human gene NAT8L encodes aspartate N-acetyltransferase (ANAT), the enzyme responsible for this activity.
What is the role of N-acetyl-L-aspartate (NAA) in the brain?
NAA is one of the most abundant metabolites in the mammalian brain, serving as an osmolyte, a precursor for the neurotransmitter NAAG, and a major source of acetyl groups for lipid synthesis during development.
What diseases are associated with L-aspartate N-acetyltransferase activity?
Mutations in NAT8L cause hypoacetylaspartia, a severe neurological disorder. The enzyme is also a therapeutic target for Canavan disease, where NAA accumulates due to aspartoacylase deficiency.
How is L-aspartate N-acetyltransferase activity measured?
It can be measured using enzymatic assays that detect NAA or CoA production, often coupled with HPLC or mass spectrometry. In vivo, 13C MRS can quantify NAA synthesis rates.
What are the substrates of L-aspartate N-acetyltransferase?
The substrates are L-aspartate and acetyl-CoA. The products are N-acetyl-L-aspartate, coenzyme A, and a proton.
Can L-aspartate N-acetyltransferase be inhibited?
Yes, several small-molecule inhibitors and bisubstrate analogs have been developed, primarily for the treatment of Canavan disease.
What is the difference between ANAT and aspartoacylase?
ANAT synthesizes NAA from aspartate and acetyl-CoA, while aspartoacylase (ASPA) degrades NAA into aspartate and acetate. They have opposing roles in NAA metabolism.
How can CRISPR be used to study L-aspartate N-acetyltransferase activity?
CRISPR can create NAT8L knockout, point-mutation knock-in, tagged knock-in, or overexpression models to study the enzyme's function, regulation, and role in disease.
Is L-aspartate N-acetyltransferase activity found outside the brain?
The activity is predominantly found in the nervous system, but low levels may exist in other tissues. The enzyme's distribution is differential across brain regions.
Conclusion
L-aspartate N-acetyltransferase activity (GO:0017188) is a fundamental molecular function that governs the synthesis of N-acetyl-L-aspartate, a critical metabolite in the nervous system. Its role in brain development, lipid synthesis, and disease is well established, with mutations in NAT8L causing hypoacetylaspartia and the enzyme serving as a therapeutic target for Canavan disease. Continued research using advanced CRISPR models and metabolic assays will further illuminate the regulation and pathophysiological significance of this activity. For researchers aiming to dissect the mechanisms and disease relevance of GO:0017188, precise genetic models are indispensable. EDITGENE's comprehensive CRISPR services, from knockout to knock-in and library screening, provide the tools needed to accelerate discovery and translate findings into therapeutic strategies.
References
- 1. Nešuta O et al.. 2021. High Throughput Screening Cascade To Identify Human Aspartate N-Acetyltransferase (ANAT) Inhibitors for Canavan Disease.. ACS Chem Neurosci 12(18):3445-3455 PMID: 34477360
- 2. Thangavelu B et al.. 2017. Design and optimization of aspartate N-acetyltransferase inhibitors for the potential treatment of Canavan disease.. Bioorg Med Chem 25(3):870-885 PMID: 28007430
- 3. Truckenmiller ME et al.. 1985. N-Acetylation of L-aspartate in the nervous system: differential distribution of a specific enzyme.. J Neurochem 45(5):1658-62 PMID: 4045470
- 4. Mutthamsetty V et al.. 2020. Development of bisubstrate analog inhibitors of aspartate N-acetyltransferase, a critical brain enzyme.. Chem Biol Drug Des 95(1):48-57 PMID: 31260162
- 5. Zyśk M et al.. 2017. Phenotype-Dependent Interactions between N-acetyl-L-Aspartate and Acetyl-CoA in Septal SN56 Cholinergic Cells Exposed to an Excess of Zinc.. J Alzheimers Dis 56(3):1145-1158 PMID: 28106547
- 6. Wiame E et al.. 2009. Molecular identification of aspartate N-acetyltransferase and its mutation in hypoacetylaspartia.. Biochem J 425(1):127-36 PMID: 19807691
- 7. Burri R et al.. 1991. N-acetyl-L-aspartate is a major source of acetyl groups for lipid synthesis during rat brain development.. Dev Neurosci 13(6):403-11 PMID: 1809557
- 8. Moreno A et al.. 2001. Direct determination of the N-acetyl-L-aspartate synthesis rate in the human brain by (13)C MRS and [1-(13)C]glucose infusion.. J Neurochem 77(1):347-50 PMID: 11279290
